Resumen
Las reacciones adversas cutáneas asociadas al uso de Lamotrigina, abarcan una gama amplia de presentaciones, desde las más leves, como es el caso del eritema multiforme mayor, hasta las más severas como la necrolisis epidérmica tóxica y el síndrome de Stevens Johnson. El presente artículo presenta un caso de un cuadro clínico clásico de reacción cutánea severa secundaria al uso de Lamotrigina, cuya evolución posterior fue favorable sin requerir manejo diferente al instaurado en casos de reacción leve. Se concluye que las manifestaciones clínicas se pueden enmascarar al realizar el diagnóstico basado solo en algunos hallazgos clínicos o evaluándolos de forma aislada, una perspectiva a considerar antes de prescribir este tipo de medicamento y su interacción con otros del mismo grupo farmacológico.
Citas
JUSTINIANO H, RAMOS AC, SÁNCHEZ JL. Pattern analysis of drug-induced skin diseases. Am J Dermatopathol 2008; 30: 352–369.
BLISS S, WARNOCK J. Psychiatric medications: Adverse cutaneous drug reactions. Clinics in Dermatology 2013; 31: 101–109.
Kocak S, Girisgin SA, Gul M et al. Stevens-Johnson syndrome due to concomitant use of lamotrigine and valproic acid. Am J ClinDermatol. 2007;8(2):107-111.
CHANG C, SHIAH IS, CHANG HA, HUANG SY. Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(1):147- 150.
TSENG H, CHANG C. Toxic epidermal necrolysis due to Lamotrigina monotherapy for bipolar disorder. Tzu Chi Med 2009; 21: 165-168.
ISHIOKA M, FURUKORI N, HASHIMOTO K, SUGAWARA N. Neuroleptic malignant syndrome induced by lamotrigine. Clinical Neuropharmacology 2013; 36(4):131-2.
HO S, CHIESA A, LEE S, ET AL. Safety and tolerability of Lamotrigine: Results From 12 Placebo-Controlled Clinical Trials and Clinical Implications. Clinical Neuropharmacology 2011;34:39–47.
WANG Z, FESSLER E, CHUANG D. Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. Acta Pharmacologica Sinica (2011) 32: 1433–1445.
HARR T, FRENCH L. Toxic epidermal necrolysis and Stevens Johnson syndrome. Orphanet Journal of Rare Diseases 2010; 5:39.
YUEN, A. Safety issues in clinical update on lamotrigine:a novel antiepileptic agent. Wells Medical International Clinical Practice series. 1992: 69-75.
Revista Panamericana de Salud Publica/Pan Am J Public Health 1997; 2(4): 279-289.
AURICH-BARRERA B, WILTON L, BROWN D, SHAKIR S. Paediatric postmarketing pharmacovigilance using prescriptionevent monitoring: comparison of the adverse event profiles of lamotrigine prescribed to children and adults in England. Drug Saf. 2010;33(9):751-63.
ARIF H, SVORONOS A, RESOR SR JR, ET AL. The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. Epilepsia. 2011; 52(10):1905- 1913.
AOUAM K, ROMDHANE F, LOUSSAIEF C, ET AL. Hypersensitivity syndrome induced by anticonvulsants: possible cross-reactivity
between carbamazepine and lamotrigine. J Clin Pharmacol. 2009;49 (12):1488-1491.
ARORA T, MEHTA AK, SHARMA KK, ET AL. Effect of carbamazepine and lamotrigine on cognitive function and oxidative stress
in brain during chemical epileptogenesis in rats. Basic & Clinical Pharmacology & Toxicology 2009; 106: 372–377
KAUR S, DOGRA A. Toxic epidermal necrolysis due to concomitant use of lamotrigine and valproic acid. Indian J Dermatol
;58:406.
SANCHEZ M, HERRANZ J, LENO C, ET AL. UGT2B7_2161C.T Polymorphism is associated with lamotrigine concentration-to-dose
ratio in a multivariate study. Ther Drug Monit 2010;35:177-184.
CHUNG J-Y, CHO J-Y, YU K-S, ET AL. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clinical pharmacology & therapeutics 2008; 83(4): 595-600.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.